Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.50 |
| ▸ | AKT1 | P31749 | 3/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628862 | 0.90 | IL23R (0.48) | KEAP1APLNRNMUR2NMUR1 | |
| SCHEMBL28923852 | 0.80 | BDKRB2 (0.50) | KEAP1NMUR2NMUR1GRB2OPRD1 | |
| SCHEMBL29367074 | 0.80 | BDKRB2 (0.50) | KEAP1NMUR2NMUR1GRB2OPRD1 | |
| SCHEMBL30751611 | 0.77 | APLNR (0.46) | APLNROPRD1 | |
| SCHEMBL30065432 | 0.77 | APLNR (0.49) | APLNR | |
| SCHEMBL29377971 | 0.76 | F2 (0.55) | APLNRGRB2OPRD1 | |
| SCHEMBL29364214 | 0.76 | KEAP1 (0.46) | KEAP1AKT1GRB2OPRD1 | |
| SCHEMBL29462901 | 0.76 | KEAP1 (0.46) | KEAP1AKT1GRB2OPRD1 | |
| SCHEMBL30882887 | 0.75 | ITGB3 (0.55) | — | |
| SCHEMBL29637996 | 0.74 | APLNR (0.46) | APLNRNMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634575-B | Development and application of complement inhibitor | 康诺亚生物医药科技(成都)有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2022127834-A1 | DEVELOPMENT AND APPLICATION OF COMPLEMENT INHIBITOR | 康诺亚生物医药科技(成都)有限公司 | 2022-06-23 | — | — | WO | disclosed |